Thirty-day results from prospective multi-specialty evaluation of carotid artery stenting using the CGuard MicroNet-covered Embolic Prevention System in real-world multicentre clinical practice: the IRON-Guard study
Francesco Speziale, Laura Capoccia, Pasqualino Sirignano, Wassim Mansour, Chiara Pranteda, Renato Casana, Carlo Setacci, Federico Accrocca, Domenico Alberti, Gianmarco de Donato, Michelangelo Ferri, Andrea Gaggiano, Giuseppe Galzerano, Arnaldo Ippoliti, Nicola Mangialardi, Giovanni Pratesi, Sonia Ronchey, Maria Ruffino, Andrea Siani, Angelo Spinazzola, Massimo Sponza, Francesco Speziale, Laura Capoccia, Pasqualino Sirignano, Wassim Mansour, Chiara Pranteda, Renato Casana, Carlo Setacci, Federico Accrocca, Domenico Alberti, Gianmarco de Donato, Michelangelo Ferri, Andrea Gaggiano, Giuseppe Galzerano, Arnaldo Ippoliti, Nicola Mangialardi, Giovanni Pratesi, Sonia Ronchey, Maria Ruffino, Andrea Siani, Angelo Spinazzola, Massimo Sponza
Abstract
Aims: The aim of the present study was to evaluate periprocedural and 30-day outcomes in a prospective series of patients treated with the CGuard Embolic Prevention System (EPS).
Methods and results: From April 2015 to June 2016, a physician-initiated prospective multicentre study was performed in 200 consecutive patients admitted for protected carotid artery stenting (CAS) and treated using the CGuard EPS in twelve vascular centres. Outcome measures were: technical success, periprocedural (0-24 hours) and post-procedural (24 hours-30 days) major and minor strokes, death, acute myocardial infarction (AMI), transient ischaemic attack (TIA), and external carotid occlusion. In three centres, consecutive diffusion-weighted magnetic resonance cerebral imaging (DW-MRI) was performed ≤72 hours prior to and within 72 hours after the intervention. A distal embolic protection device was employed in 182 patients (91%). Technical success was 100%. No death, AMI or major stroke occurred periprocedurally. There were two TIAs and five periprocedural minor strokes (2.5%), including one thrombosis solved by surgery. In the remaining patients (199/200; 99.5%) one-month follow-up duplex ultrasound revealed optimal technical results. Post-procedural clinical follow-up was uneventful. No external carotid artery occlusion occurred. New post-procedural DW-MRI lesions were detected in 12 patients out of 61 (19.6%), including bilateral in five (8.2%) and isolated ipsilateral in six (9.8%), whereas one patient (1.6%) had contralateral only lesions.
Conclusions: Multicentre multi-specialty use of the CGuard EPS in routine clinical practice was associated with no major periprocedural neurologic complications and a total elimination of post-procedural neurologic complications by 30 days.
Source: PubMed